Author Archive

Radio Filters and the Cellular Broadband Challenge

Thursday, January 17th, 2013

The following thoughts from an article by Mark Bole CEO of Talu Investee, Mesaplexx Pty Ltd.  The time is right for disruptive radio filter technology…..

Delivering LTE Coverage and Capacity Gains –

Why Radio Filters Matter

Unprecedented growth in mobile data traffic continues to increase expectations on LTE technology. The pressure is on the operator and supporting vendor community to maximise spectrum efficiency to recoup substantial financial investment and sustain profitability. However, few industry experts expect LTE to carry the data burden in isolation; with many pointing to a collaboration of supporting technologies and techniques, to drive spectral efficiency and maximise network coverage and capacity to meet rising demand.

Active antenna systems (AAS), small cells and other compact radio systems are good examples of these supporting technologies. All are focused on generating additional network coverage and capacity and targeting it towards congested areas of the network. These technologies will become commonplace across next generation networks as part of a heterogeneous network layer.

Given the complexities of next generation network architectures, technologies such as AAS and carrier grade small cells must overcome some technical challenges if they are to reach their full potential. This means removing some of the existing limitations that stem from their existing radio components, and in particular, their radio filters.

Radio filters critical in achieving spectral efficiency

All filters share the same purpose and function – driving spectral efficiency. In the radio access node or base station, the filter selects which signals, in which band, reach the radio receiver, whilst rejecting unwanted frequencies. They achieve this by enabling radio systems to share the same spectrum within the same geographic area. Filters enable mobile operators to partition available spectrum and reduce the need for guard bands to be used to protect against interference caused by adjacent bands. By achieving this, and by blocking spectrum at the band boundaries, filters can maintain a greater number of channels in the band, thus maximising spectrum usage.

Three key challenges facing filter design – size, weight and performance

Equipment vendors are striving to improve the performance of their radio systems whilst making them smaller, lighter and more efficient. Other system components are being successfully miniaturised but infrastructure vendors continue to struggle when it comes to effectively shrinking radio filters. This is a significant obstacle in creating system architectures that meet the needs of the market. This is especially true given that the filters may have to offset any deficiencies caused by the miniaturisation of the other radio components.

Existing filters in AAS and small cells are too large and too heavy. AAS require multiple transceivers to facilitate advanced beam steering techniques and support multiple network technologies on multiple bands (multimode).  This means several filters need locating in the antenna housing, and to achieve this without increasing the overall size and weight of the antennas, they need to be made smaller and lighter. It is also critical that filters do not absorb too much signal power. Doing so increases loss and weakens critical signal strength while generating too much heat. Many of these challenges also apply to small cells, limiting performance, coverage and capacity.

 A breakthrough in radio filter design

The challenge of effective filter miniaturisation has now been overcome. A new compact, cool running, low loss, high isolation filter has now been developed that improves sensitivity and handles much more power than existing technologies. This filter uses multimode resonators, joined together by sophisticated coupling techniques to optimise performance. In fact, these coupling techniques effectively enable the re-use of the same resonator many times.  This dramatically reduces the size of the filter.

Increasing capacity and coverage

The technology will enable operators to enjoy significant capacity improvements. This is achieved by reducing the insertion loss of filters and duplexers, reducing interference and improving the signal to noise ratio. By reducing insertion loss, the filter also improves network coverage by maximising the power amplifier throughput radiated from the base station, increasing the downlink range. It also improves the sensitivity of the system and the maximum range at which a mobile signal can be received and the range at which a device can be used. Handsets will also be able to negotiate a higher throughput at any given range or be able to reduce their transmitted power, thereby extending battery life. This enables better signal strength across wider distances, reducing the number of small cells and macro base stations required.

Power – delivering more with less

Conventional compact filter technologies are often unable to handle more than a few watts of power. This is unsuitable for a significant proportion of cellular networks, including many carrier grade small cells. However, increasing the amount of power causes unwanted heat within the system. This heat can limit overall performance and be expensive to remove. The latest filter technology is capable of reducing this heat by up to 50 per cent – it dissipates a much lower proportion of its input power (just 20 per cent) as heat. This not only leads to an increase in base station capacity but also increases power handling capability and reduces the cost and complexity of dissipating heat. By wasting less of the input power, more power is transmitted in the network. This enables power amplifiers to operate more efficiently, enabling cleaner, greener and more efficient networks and devices.

The ability to successfully miniaturise radio filters has significant implications for the vendor and operator community. The commercial reality at present is that existing radio systems are suffering from a variety of issues that can all be traced back to the performance of the filter. Some face heat challenges, while others are struggling with power output or achieving true multi-band capability. New filter innovation, such as xCube™ from Mesaplexx, enables network vendors to achieve the best possible network architecture by simultaneously solving a variety of challenges. The benefits include increased network coverage or capacity, improving power handling, enhancing sensitivity, reducing heat, lowering power usage, enabling multiband capability and delivering lighter, more environmentally friendly systems. These filters give the mobile industry real cause for optimism.

 

Threatmetrix Recognised in the Top 15 Security Startups for 2013

Monday, January 14th, 2013

San Jose based internet threat company, Threatmetrix, has been recognised for its continued stellar presence in the online secutiry domain.

http://www.businessinsider.com/15-most-important-security-startups-2013-1?op=1

 

Why Publishers Should Hate Apps But Don’t (Yet)

Saturday, January 12th, 2013

AdGent Digital CEO, Cam Yuill, delves into the world of publishers, content subscriptions, and HTML5.

http://www.huffingtonpost.com/cameron-yuill/why-publishers-should-hat_b_2457882.html

Datacastle a recognised Cloud Innovator

Friday, January 11th, 2013

Datacastle Corporation Vice President, Craig Blessing, talks with Microsoft TechNet Radio about the use of Microsoft Azure to Protent Business Data.

http://channel9.msdn.com/Shows/TechNet+Radio/TechNet-Radio-Cloud-Innovators–How-Datacastle-uses-Windows-Azure-to-Protect-Business-Data

 

ThreatMetrix Achieves Record Revenue, Increased Transaction Volume and Customer Growth in 2012

Wednesday, January 9th, 2013

 Acquisition of TrustDefender, Successful Funding Round and Key Additions to the Management Team Contributed to ThreatMetrix’s Exponential Growth

San Jose, CA – January 8, 2013 – ThreatMetrix™, the fastest-growing provider of integrated cybercrime prevention solutions, today announced its exponential growth in 2012 highlighted by the acquisition of TrustDefender, record revenue, billings and transaction volume, and the addition of hundreds of new customers.

“The acquisition and successful integration of TrustDefender kicked off our most impressive year of growth to date,” said Reed Taussig, president and CEO, ThreatMetrix. “We’ve now delivered 16 consecutive quarters of growth in customer billings. We look forward to another exceptional year protecting our customers from fraud, malware and the global threat of cyberterrorism in 2013.”

ThreatMetrix made significant advances in several key areas in 2012, including:

•        Acquired TrustDefender: ThreatMetrix acquired TrustDefender, a leader of secure browsing technology, to stop man-in-the-browser (MitB) attacks and prevent malware attacks for ThreatMetrix’s growing customer base.

•        Secured New Customers: The company added more than 500 new customers, both directly and in conjunction with its extensive partner channel in 2012; the average new account value of these customers was up 50 percent over 2011.

•        Expanded Presence and Marketshare in Financial Services:  Customer billings and revenues for financial services increased from 20 percent of total contribution to more than 40 percent of total contribution in 2012. ThreatMetrix expects that the financial services market will contribute more than 60 percent of revenues in 2013.

•        Experienced Record Transaction Volume: In 2012, ThreatMetrix experienced 500 percent year-over-year transaction volume growth.

•        Achieved Record Recurring Revenue: The company’s recurring customer revenue in 2012 was 300 percent what they were in 2011, which is a testament to the success ThreatMetrix customers are experiencing with its products.

•        Released New Products and Features: Following the acquisition of TrustDefender, ThreatMetrix released the ThreatMetrix Cybercrime Defender Platform, which helps companies protect customer data and secure against fraud, malware, data breaches, MitB and Trojan attacks. The platform consists of advanced cybersecurity technologies, including TrustDefender™ ID, which is cloud-based, real-time device identification, malware protection with TrustDefender™ Cloud and TrustDefender™ Client, as well as TrustDefender™ Mobile for smartphone applications. In August, ThreatMetrix updated the platform to become the only solution on the market that provides virtual private network (VPN) and phishing detection with advanced device identification and malware protection to combat cybercriminals.

•        Closed Series D Funding: ThreatMetrix secured $18 million in a Series D financing round led by August Capital. ThreatMetrix’s existing investors – Tenaya Capital, US Venture Partners and CM Capital – also participated in the investment.

•        Hired Strategic Management: Frank Teruel joined as vice president of finance and CFO and John Kirst joined as senior vice president of field operations. Andreas Baumhof, executive director, CEO and co-founder of TrustDefender, assumed the role of senior vice president of engineering and chief technology officer.

•        Launched ThreatMetrix Labs: ThreatMetrix launched ThreatMetrix Labs in February, which generates in-depth reports on the latest capabilities of malware that targets financial institutions, merchants and online businesses.

•        Granted Two New U.S. Patents: ThreatMetrix was granted two new patents by the United States Patent Office to enhance cybercrime detection and prevention. For several years, patented technology and ongoing product enhancements have enabled ThreatMetrix to lead the industry with continuous innovation in cybercrime detection and prevention solutions.

•        Hosted 2012 Fraud Fighters Summit: ThreatMetrix hosted its second annual Fraud Fighters Summit in October, uniting more than 200 industry leaders in the fight against cybercrime.

•        Named to Wall Street Journal’s “Next Big Thing” List: In October, ThreatMetrix was named to the Wall Street Journal’s “Next Big Thing” list of the top 50 start-ups in the U.S. The third-annual ranking of venture-capital-backed U.S. companies was compiled from a list of more than 5,900 candidates.

“Cybercriminals have the financial services value chain in their crosshairs, and the threats to government and insurance institutions are rapidly mounting as well,” said Julie Conroy, research director, Aite Group. “Unique strains of malware topped 100 million in 2012, and the trajectory is growing at a frightening pace.  It is incumbent upon financial institutions, merchants, and government entities to protect both themselves and their customers with a robust approach that includes multiple, complementary layers of security.  As we’ve seen time and time again, it’s all too easy for fraudsters to circumvent any single point solution.”

 

Bayer HealthCare Introduces ResultixTM, a New Tick Killing Solution for Dogs and Cats

Thursday, November 29th, 2012

Bayer HealthCare Introduces ResultixTM, a New Tick Killing Solution for Dogs and Cats

  • Pet owners and veterinarians can kill ticks without the ick!

Shawnee, Kans, November 29, 2012 – Today, Bayer HealthCare LLC Animal Health
Division made it easy to kill ticks on dogs and cats with Resultix, a new, simple spray-on
formula that kills attached or crawling ticks. Bayer HealthCare debuted Resultix at the
opening of BarkWorld Expo, a pet social media conference in Atlanta, Ga on October 26.

Resultix provides an effective way to kill ticks and can be used as often as needed. Just
two sprays of Resultix will dissolve the outer wax layer that covers the hard shell (cuticle)
of the tick, resulting in uncontrollable water loss and death of the tick. The tick will be
dead within three hours; it may either fall off of the dog or cat, or be immobile when
removed.

Resultix, available in an easy to transport 20 mL bottle, will be sold through veterinary
clinics, pet specialty stores and online retailers.

Ticks are common parasites that feed on dogs and cats alike and may infest pets in very
large numbers.

“A tick can cause serious problems for pets and dealing with tick infestations can be
stressful for both pet owners and their pets,” said Cristiano von Simson, DVM, MBA,
Director of Veterinary Technical Services at Bayer HealthCare LLC, Animal Health
Division, North America. “Resultix provides a convenient and easy to apply alternative to
traditional tick removal for pet owners and veterinarians who spot one or more ticks on a
dog or cat.”

Bayer HealthCare collaborated with Piedmont Pharmaceuticals to bring Resultix to
market.

Bayer HealthCare Introduces ResultixTM, a New Tick Killing Solution
for Dogs and Cats

“We are very pleased to celebrate the first product launch resulting from our partnership
with Bayer HealthCare,” said Roland Johnson, Chairman and CEO, Piedmont
Pharmaceuticals. “The technology in Resultix created by Piedmont truly makes it an
effective tick killing product.”

For more information on Resultix, visit killthetick.com, where you can also learn how to
join the PetParents.com community for access to helpful pet tips and resources.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health
care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with
annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative
companies in the healthcare and medical products industry and is based in Leverkusen,
Germany. The company combines the global activities of the Animal Health, Consumer
Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to
discover, develop, manufacture and market products that will improve human and animal
health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec
31, 2011) and is represented in more than 100 countries. Find more information at
www.bayerhealthcare.com.

Pharmaceutical Manufacturer to Create 14 Jobs in Guilford County

Monday, September 17th, 2012

Beverly Eaves Perdue
Governor

State of North Carolina
Office of the Governor
20301 Mail Service Center • Raleigh, NC 27699-0301

Sept. 17, 2012

Contact: Chris Mackey

Office: (919) 733-5612

Pharmaceutical Manufacturer to Create 14 Jobs in Guilford County

State Grant Helps Biotech Company Expand in Greensboro

RALEIGH – Gov. Bev Perdue today announced that Piedmont Pharmaceuticals LLC, a manufacturer of pharmaceutical products, will expand its operations in Guilford County. The company plans to create 14 jobs and invest $279,000 over the next three years in Greensboro. The project was made possible in part by an $88,000 grant from the One North Carolina Fund.

“My top priority is creating jobs,” said Gov. Perdue. “Our highly-skilled workforce and strong business climate have allowed the biotech industry to thrive in North Carolina. It’s no surprise that our state has one of the fastest growing biotech clusters in the nation.”

Piedmont Pharmaceuticals, headquartered in Greensboro, is a privately-held pharmaceutical development company that focuses on animal health products. The company’s expertise is in parasitology and drug delivery technologies. Piedmont Pharmaceuticals currently employs 12 people at its Greensboro laboratory.

Salaries will vary by job function, but the average annual wage for the new jobs will be $108,429, plus benefits. The Guilford County average annual wage is $40,196.

“North Carolina was selected for Piedmont’s next expansion since it has a talented pool of experienced life science professionals and a variety of organizations, including the N.C. Biotechnology Center and N.C. Department of Commerce, who were very supportive when Piedmont was in the start up phase,” said Roland Johnson, CEO of Piedmont Pharmaceuticals.

The One NC Fund provides financial assistance, through local governments, to attract business projects that will stimulate economic activity and create new jobs in the state. Companies receive no money up front and must meet job creation and investment performance standards to qualify for grant funds. These grants also require and are contingent upon local matches.

“Today’s job announcement is great news for Guilford County,” said Sen. Don Vaughn of Greensboro. North Carolina’s investments in workforce development, infrastructure and education mean Piedmont Pharmaceuticals can find the skilled, trained workers they need to thrive.”

North Carolina continues to have a top-ranked business climate. Through Gov. Perdue’s JobsNOW initiative, the state works aggressively to create jobs, train and retrain its workforce, and lay the foundation for a strong and sustainable economic future.

Through use of the One NC Fund, more than 60,000 jobs and $11 billion in investment have been created since 2001. Other partners that helped with this project include: the N.C. Department of Commerce, N.C. Community Colleges, N.C. Biotechnology Center, Guilford County, City of Greensboro and the Greensboro Economic Development Alliance.

For more information about Piedmont Pharmaceuticals, including job opportunities, go to http://www.piedmontpharma.com/.

Piedmont and Hisun Sign Agreement to Develop Animal Pharmaceuticals

Thursday, March 15th, 2012

NEW YORK, March 15, 2012 /PRNewswire/ – Piedmont Pharmaceuticals, a privately held strategic pharmaceutical development, licensing, and marketing company headquartered in Greensboro, N.C., USA, and Zhejiang Hisun Pharmaceuticals (SSE stock code 600267), a leading Chinese pharmaceutical company headquartered in Zhejiang, China, announce the signing of a joint agreement to develop companion animal health pharmaceuticals for China and other markets worldwide.

“New products are the lifeblood of every pharmaceutical company,” says Roland Johnson, chairman and CEO of Piedmont Pharmaceuticals. “Hisun is a globally-recognized pharmaceutical provider that demonstrates excellence in every facet of their business operations. This partnership will allow the team at Piedmont to develop and bring even more innovative animal health products to strategic business partners and pet owners worldwide.”

Hua Bai, CEO and chairman of Hisun Pharmaceuticals, notes, “Hisun is very pleased to enter this partnership with Piedmont Pharmaceuticals. The Piedmont team has tremendous depth of expertise and 25 years of proven success with some of the most successful animal health products ever introduced. This product development agreement is a significant component of our strategy to become a leading global supplier of animal health pharmaceuticals. Products emerging from this collaboration will not only help Chinese consumers ensure the health of their pets, but will serve pet owners in other global markets as well.”

Serving a growing market

Current estimates place China’s pet population at 200 million, with that number expected to reach 500 million by 2015.[i] China is the world’s second largest economy behind the U. S., and in the last 30 years, economic growth in China has averaged 8 percent gross domestic product (GDP) annually.[ii] Many analysts predict that China will become the largest economy in the world this century.

Combining strengths

Formed by a group of industry veterans, Piedmont Pharmaceuticals develops and achieves regulatory approval for its innovative animal health and human products, then licenses them to strong commercial partners. Piedmont has licensed a number of its novel animal health products to U.S.-based Pfizer, U.K.-based Dechra Pharmaceuticals, and Germany-based Bayer Animal Health.

Based on sales revenues, members of Piedmont’s team have been involved at some level — including conception, development, regulatory, or marketing — with products that represent more than 10 percent of total dollars spent in the companion animal veterinary pharmaceuticals market in the U.S. today.

Hisun supplies active pharmaceutical ingredients (APIs) to some of the world’s largest pharmaceutical companies, including Pfizer, Merck, Novartis, Eli Lilly, and Alpharma.[iii] In February 2011, Hisun entered into a joint venture framework agreement with Pfizer, the world’s largest pharmaceutical company, to develop products for human health.

Piedmont and Hisun will combine their strengths in research, development, regulatory, manufacturing, and distribution to improve the health and well-being of companion animals worldwide. Committed to meeting the manufacturing needs of its global expansion policy, Hisun currently has more than 200,000 square feet of new space under construction at the Fuyang site in China, including 35,000 square feet dedicated to the new animal health business.

About Hisun

Hisun is a leading biopharmaceutical group focused on improving patient wellbeing and quality of life. Headquartered in Taizhou (Zhejiang, China), the company currently employs more than 3,800 people. Hisun’s operations strictly follow cGMP and received ISO 14000 certification in 2001. To date, more than 40 of the company’s products have passed certification by the FDA (US), EDQM (EU), TGA (Australia), KFDA (Korea), etc., and are sold in more than 30 countries. The company opened its U.S. headquarters in Princeton, N.J., in 2010. For more information, visit www.hisunusa.com.

About Piedmont

Piedmont Pharmaceuticals LLC is a Greensboro, N.C.-based strategic pharmaceutical development and licensing company focused on human and animal health therapeutics with specific expertise in parasitology and drug delivery systems. The company discovers, develops, and achieves regulatory approval for innovative animal health and human health products, and then licenses them to strong commercial partners. Since its inception in 2001, Piedmont has licensed multiple novel patented delivery platforms to strategic partners. Through licensing agreements, Piedmont has products currently marketed in numerous countries. For more information, visit www.piedmontpharma.com.

[i] China International Business, January 19, 2010.
[ii] Economy Watch, June 2010.
[iii] www.KnowledgeAtWharton.com.cn, January 30, 2008.

Contact: Alice Coram, 919.293.0243, ext. 201

SOURCE Piedmont Pharmaceuticals LLC